GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Bumble

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at online services stocks GoodRx Holdings Inc (NASDAQ:GDRX) and Bumble Inc (NASDAQ:BMBL).

2 Tech Stocks to Watch Under $20

RADNOR, Pa. , May 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period").

GoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

LOS ANGELES , May 15, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ: GDRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced a new direct contracting agreement with The Kroger Co. to deliver improved prescription pricing at more than 2,200 Kroger family pharmacy locations nationwide. “We are excited to renew our relationship with Kroger,” said Scott Wagner, Interim CEO of GoodRx. “Kroger has been a valuable participant in the GoodRx marketplace over the years and an innovator in.

GoodRx and Kroger Sign Direct Contracting Agreement

NEW YORK , May 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GoodRx Holdings, Inc. (NASDAQ: GDRX). Shareholders who purchased shares of GDRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK , May 13, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the "Class Period"), of the important June 21, 2024 lead plaintiff deadline . SO WHAT: If you purchased GoodRx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages GoodRx Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GDRX

NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=79464&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on GoodRx Holdings, Inc. (GDRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=79307&wire=1 or contact Joseph E. Levi, Esq.

GoodRx Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights – GDRX

NEW YORK--(BUSINESS WIRE)---- $GDRX #GDRX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”), of the important June 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased GoodRx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen.

GDRX NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRX

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Stephanie Davis - Barclays Daniel Grosslight - Citi Lisa Gill - JP Morgan Charles Rhyee - TD Cowen Stan Bernstein - Wells Fargo Securities Scott Schoenhaus - KeyBanc Sean Dodge - RBC Capital Markets John Ransom - RJF John Park - Morgan Stanley George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRX First Quarter 2024 earnings call. At this time, a reminder, today's conference is being recorded.

GoodRx Holdings, Inc. (GDRX) Q1 2024 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $197.9 million Net loss of $1.0 million; Net loss margin of 0.5% Adjusted Net Income1 of $32.6 million; Adjusted Net Income Margin1 of 16.5% Adjusted EBITDA1 of $62.8 million; Adjust.

GoodRx Reports First Quarter 2024 Results

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=78594&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds GoodRx Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 – GDRX

SAN DIEGO--(BUSINESS WIRE)---- $GDRX #GDRX--Robbins LLP is Investigating the Allegations that GoodRx Holdings, Inc. (GDRX) Misrepresented its Business Prospects.

GDRX Stockholders with Significant Losses Should Contact Robbins LLP for Information About the GoodRx Holdings, Inc. Securities Class Action

NEW YORK , May 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GoodRx Holdings, Inc. (NASDAQ: GDRX). Shareholders who purchased shares of GDRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders that lost money on GoodRx Holdings, Inc.(GDRX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

NEW YORK , May 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRX

NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) and reminds investors of the June 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In GoodRx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in GoodRx stock or options between September 23, 2020, and November 8, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRx

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 21, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). Investors suffering losses on their GoodRx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). GoodRx investors have until June 21, 2024 to file a lead plaintiff motion. If you suffered a loss on your Go.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

GoodRx Holdings, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the GDRX Securities Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). GoodRx investors have until June 21, 2024 to file a lead plaintiff motion. Investors suffering losses on their GoodRx investments are encouraged to contact the Law Offices of Howard G. S.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning GoodRx business and prospects, resulting in its stock trading at inflated prices.

GDRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

News for GoodRx Holdings Stock (GDRX)